Expectations trend
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsNASDAQConsumer DiscretionaryRestaurantsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for NATH yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Net income at or above $2.81M in fiscal Q4 2026 | Net income reached $2.81M in 2026-Q4. | Broken | Net income falls below $2.81M in any quarter after 2026-Q4 | Net income: $8.829M FY2027-Q1; GAAP. Published target: >= $2.81M. The stored target says 2026-Q4; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Aug 7, 20268,829,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a small-cap branded food business with a durable premium versus peers, rather than a turnaround or a deeply discounted situation. The long-term thesis is intact because recent financial performance remains in the top half of its industry, though confidence has eased to medium and management execution has been volatile.
The valuation is about 1.33 times the peer level, reflecting a durable premium, while the expectations gap is modest. The evidence labels this premium justified, with low priced-in fragility, so the market appears to recognize the business’s strengths without pricing in the full range of execution risks.
Near term, recent financial performance is strong, but earnings quality is fragile and earnings surprises have been erratic. Management completed the Smithfield acquisition, while branded product sales grew but operating income declined, and full-year licensing royalties were nearly flat. The next guidance update and the legal event disclosed on October 26 are risks to watch; the supplied evidence gives little detail on the legal matter.
Over the next one to three years, the thesis depends on turning branded sales growth into stronger segment profitability and sustaining licensing royalties after the acquisition. A guidance cut would be a meaningful negative, while continued strength from consumer-sector bellwethers could support the sector backdrop; weakness from those companies could remove that tailwind.
The multi-year view remains intact, supported by strong recent performance and completion of the acquisition, but mixed execution and fragile earnings quality limit confidence. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company keeps profit margins steady near $4.68M operating income. |
| Under Pressure |
| Operating income falls below $4.0M in any quarter after 2026-Q4 |
Operating income: $12.668M FY2027-Q1; GAAP. Published target: ~$4.68M. The stored target says 2026-Q4; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Aug 7, 202612,668,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth to at least $35.07M in fiscal Q4 2026 | A primary condition in Nathan's Famous, Inc.'s published investment case. The stated target is >= $35.07M. | Intact | Revenue falls below $30.79M in any quarter after 2026-Q4 | Revenue: $54.062M FY2027-Q1; GAAP. Published target: >= $35.07M. The stored target says 2026-Q4; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Aug 7, 202654,062,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.